Pfizer’s Hospira has cleared any possible repercussions from the ‘at-risk’ launch of its biosimilar pegfilgrastim product, Nyvepria (pegfilgrastim-apgf), after itself and originator Amgen submitted a stipulation to dismiss all claims and counterclaims litigation.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?